Rodolfo Rodriguez
Optometrist · North Bergen, NJNPI 1437198009
Payments from drug & device makers
Across 559 payments — averaging $435.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$94K
- Tarsus Pharmaceuticals, Inc.$61K
- Bausch & Lomb Americas Inc.$34K
- Oyster Point Pharma, Inc.$21K
- Alcon$18K
- AbbVie$13K
- plus $3K from 18 others
What the payments were for
- Consulting fees$10,9755%
- Speaking & faculty fees$190,10378%
- Travel & lodging$28,63912%
- Food & beverage$13,8116%
- Education$360%
- Gifts$370%
- Entertainment$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 177 | $94,293 |
| Tarsus Pharmaceuticals, Inc. | 83 | $61,226 |
| Bausch & Lomb Americas Inc. | 67 | $33,573 |
| Oyster Point Pharma, Inc. | 61 | $21,018 |
| Alcon | 38 | $17,511 |
| AbbVie(2 entities) | 52 | $13,217 |
| Kala Pharmaceuticals, Inc. | 17 | $927 |
| Eyevance Pharmaceuticals LLC | 6 | $337 |
| Novartis | 22 | $286 |
| Sanofi | 2 | $186 |
| Dompe US, Inc. | 4 | $184 |
| Biotissue Holdings Inc. | 2 | $128 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $121 |
| Sight Sciences, Inc. | 2 | $118 |
| Visioneering Technologies, Inc. | 1 | $96 |
| Harrow Eye, LLC | 3 | $83 |
| Coopervision Inc. | 2 | $81 |
| Amgen | 1 | $76 |
| Shire North American Group Inc | 4 | $55 |
| Optos, Inc. | 1 | $29 |
| Aerie Pharmaceuticals, Inc. | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$243,630 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CequaCyclosporine | 895 | $849,724 |
| RestasisCyclosporine | 426 | $502,330 |
| XdemvyLotilaner | 231 | $432,575 |
| MieboPerfluorohexyloctane/Pf | 309 | $328,898 |
| XiidraLifitegrast | 257 | $320,149 |
| LumiganBimatoprost | 324 | $174,449 |
| TyrvayaVarenicline Tartrate | 75 | $79,005 |
| VyzultaLatanoprostene Bunod | 96 | $58,879 |
| VevyeCyclosporine | 52 | $40,074 |
| Cyclosporine | 35 | $22,791 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $20,657 |
| Alphagan PBrimonidine Tartrate | 80 | $20,145 |
| RhopressaNetarsudil Mesylate | 30 | $16,862 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $13,881 |
| IyuzehLatanoprost/Pf | 16 | $12,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sun Pharmaceutical Industries Inc.Cequa | $94,293 | $849,724895 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $13,217 | $717,582865 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $33,573 | $707,925662 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $61,226 | $432,575231 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $21,018 | $79,00575 claims |
| Harrow Eye, LLCVevye | $83 | $40,07452 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $27 | $30,74357 claims |
| AlconSimbrinza, Azopt | $17,511 | $18,21936 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $927 | $7,07615 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $121 | $1,88915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in North Bergen
- Kerry GelbWoodbridge$264K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
- Ada NohCinnaminson$74K
- Kristen FryTeaneck$66K
- Melanne RosettaIselin$66K
- Frank BuccieroSpringfield$57K
- Debbie EdegranCloster$53K
- Victoria DzurinkoDeptford$47K
- Michael McAleeseHowell$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.